From: Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer
Factors | All patients | No. of patients (%) | P | |
---|---|---|---|---|
 | N= 181(%) | mTOR negative | mTOR positive |  |
Age(y) | Â | Â | Â | .256 |
< 60 | 95(52.5) | 50(56.8) | 45(48.4) | Â |
≥60 | 86(47.5) | 38(43.2) | 48(51.6) |  |
Sex | Â | Â | Â | .926 |
Male | 129(71.3) | 63(71.6) | 66(71.0) | Â |
Female | 52(28.7) | 25(28.4) | 27(29.0) | Â |
Site | Â | Â | Â | .053 |
Upper | 77(42.5) | 33(37.5) | 44(47.3) | Â |
Middle | 28(15.5) | 10(11.4) | 18(19.4) | Â |
lower | 74(40.9) | 43(48.9) | 31(33.3) | Â |
Diffuse | 2(1.1) | 2(2.3) | 0(0.0) | Â |
Tumor size | Â | Â | Â | .172 |
≤ 4 cm | 63(34.8) | 35(40.0) | 28(30.1) |  |
> 4 cm | 118(65.2) | 53(60.0) | 65(69.9) | Â |
Borrmann type | Â | Â | Â | .398 |
Early stage | 7(3.9) | 6(6.8) | 1(1.1) | Â |
I | 4(2.2) | 2(2.3) | 2(2.1) | Â |
II | 65(35.9) | 31(35.2) | 34(36.6) | Â |
III | 101(55.8) | 47(53.4) | 54(58.1) | Â |
IV | 4(2.2) | 2(2.3) | 2(2.1) | Â |
grading | Â | Â | Â | .999 |
1 | 4(2.2) | 2(2.3) | 2(2.1) | Â |
2 | 55(30.4) | 27(30.7) | 28(30.1) | Â |
3 | 116(64.1) | 56(63.6) | 60(64.5) | Â |
4 | 6(3.3) | 3(3.4) | 3(3.3) | Â |
Pathologic T classification | Â | Â | Â | .168 |
T1 | 17(9.4) | 12(13.6) | 5(5.4) | Â |
T2 | 35(19.3) | 18(20.5) | 17(18.3) | Â |
T3 | 119(65.7) | 55(62.5) | 64(68.8) | Â |
T4 | 10(5.5) | 3(3.4) | 7(7.5) | Â |
Pathologic N status | Â | Â | Â | .008 |
N negative | 44(24.3) | 29(33.0) | 15(16.1) | Â |
N positive | 137(75.7) | 59(67.0) | 78(83.9) | Â |
Pathologic stage (pTNM) | Â | Â | Â | .026 |
I | 26(14.4) | 17(19.3) | 9(9.7) | Â |
II | 47(26.0) | 28(31.8) | 19(20.4) | Â |
III | 100(55.2) | 41(46.5) | 59(63.4) | Â |
IV | 8(4.4) | 2(2.3) | 6(6.5) | Â |